Impact of direct-acting antiviral therapy on metabolic profiles and adiponectin serum level in different categories of patients with chronic hepatitis C infection

Abstract Background Infection with the hepatitis C virus (HCV) is a worldwide health problem. HCV infection linked to variety of metabolic abnormalities as it interferes lipid metabolism, causing steatosis and wide range adipocytokine alterations, well impairing glucose resulting in rising prevalence insulin resistance (IR) type 2 diabetes. Over last few years, numerous oral anti-HCV medicines (direct-acting antivirals; DAAs) have been introduced. With DAA therapy, can now be eradicated from infected host within 12 weeks. There need for more research because there minimal information on effects therapy profiles, adiponectin levels. Thus, purpose this study was see how direct-acting antivirals (DAAs) affected profiles serum levels different categories Egyptian patients chronic infection. This included 100 who were separated into two groups. Group I consisted 50 treated weeks sofosbuvir, daclatasvir, ribavirin). II ombitasvir, paritaprevir, ritonavir/ribavirin. regimen chosen these had an eGFR 30 ml/min. Fasting (total cholesterol, triglyceride, HDL, LDL), (fasting blood sugar, fasting insulin, HOMA-IR, HbA1C), measured before after end treatment. Results Statistical analysis data showed significant difference profile group treatment, we found reduction triglycerides treatment (113.2 ± 22.9 mg/dL vs 105.6 23.2 mg/dL, P < 0.001) elevation total LDL, HDL (TC: 153.2 20.1 174.1 19 0.001; LDL: 74.7 9.9 93.3 HDL: 54.6 10.1 57.2 10.3 0.010). But II, no We also HBA1C insulin: 11.4 3.3 (µU/L)/ml 9.7 2.2 (µU/L)/ml, HOMA-IR: 2.7 0.9 0.6, HBA1C: 5.6 0.4 5.4 0.3, 0.003). Also, that changes level either or Conclusion clearance DAAs impact at could depend used stage liver disease, associated conditions patients. However, are unaffected.